Substance / Medication

Panobinostat

Overview

Active Ingredient
panobinostat
RxNorm CUI
1603350

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a.
Armani-Tourret Marie, Gao Ce, Hartana Ciputra Adijaya et al. · Cell · 2024
PMID: 38367616RCTFull text (PMC)
A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer.
Feld Ronald, Woo Margaret M, Leighl Natasha et al. · Cancer Chemother Pharmacol · 2013
PMID: 24013574RCT
The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.
Shapiro Geoffrey I, Frank Richard, Dandamudi Uday B et al. · Cancer Chemother Pharmacol · 2012
PMID: 22057852ObservationalFull text (PMC)
Successful treatment of refractory metastatic neuroblastoma with panobinostat in combination with chemotherapy agents and iodine-131-meta-iodobenzylguanidine therapy.
Zareifar Soheila, Shakibazad Nader, Zekavat Omid Reza et al. · J Oncol Pharm Pract · 2020
PMID: 31156056Case Report
Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD).
Sekiguchi Yasunobu, Takizawa Haruko, Inano Tadaaki et al. · Int J Hematol · 2017
PMID: 28353192Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Panobinostat (substance)
SNOMED CT
429068009
UMLS CUI
C1998098
RxNorm CUI
1603350

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.